Local or Whole Body Hyperthermia
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy describes coverage and medical necessity criteria for local hyperthermia used with radiation therapy for superficial cutaneous or subcutaneous malignancies and states the noncoverage/insufficient evidence stance for whole-body hyperthermia; it applies to Medicare Advantage and Commercial product lines.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Local hyperthermia — Medical necessity
Covered when ALL of the following are met (product-dependent):
Medicare Advantage-specific statement; therapy is not covered when online authorization criteria are not met.
Commercial products: local hyperthermia is not medically necessary when used alone or in connection with chemotherapy.
Whole-body hyperthermia — Not covered / Not medically necessary
No specific CPT code; report as unlisted when applicable.
Local hyperthermia is not medically necessary when used alone or when used in connection with chemotherapy; the evidence is insufficient to determine effects on health outcomes. (This applies to Commercial products and to situations where the medical criteria are not met.)
Whole-body hyperthermia therapy is not covered / not medically necessary for Medicare Advantage Plans and is considered not medically necessary for Commercial products because the evidence is insufficient to determine the effects on health outcomes.
Reiterating the policy stance: local hyperthermia is considered not medically necessary when provided as a sole modality or in combination with chemotherapy due to insufficient evidence of benefit. When local hyperthermia is used in connection with radiation therapy and the applicable medical criteria are met, coverage may be provided per product rules.
For whole-body hyperthermia, the policy is explicit that this modality is not covered for Medicare Advantage and is not medically necessary for Commercial products; the clinical evidence is inadequate to support its use, and there is no specific CPT code for whole-body hyperthermia (report as an unlisted procedure when applicable).
Procedure and Billing Codes
| 77600 | Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less). |
| 77605 | Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm). |
| 77610 | Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators. |
| 77615 | Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators. |
| 77620 | Hyperthermia generated by intracavitary probe(s). |
| unlisted | No specific CPT procedure code for whole-body hyperthermia; report using an unlisted code. |
Prior Authorization, Documentation, and Denial Risk
Obtain prior authorization for Medicare Advantage; recommend for Commercial
Prior authorization is required for Medicare Advantage Plans; prior authorization is recommended for Commercial Products. When medical criteria in the online authorization tool are met, the listed local hyperthermia CPT codes (77600, 77605, 77610, 77615, 77620) should be authorized. There is no specific CPT code for whole‑body hyperthermia; report whole‑body procedures using an unlisted code when applicable.
- Medicare Advantage: prior authorization required and medical necessity determined by the online authorization tool.
- Commercial: prior authorization recommended; medical necessity when criteria are met.
- Covered CPT codes for local hyperthermia: 77600, 77605, 77610, 77615, 77620.
- Whole‑body hyperthermia: no specific CPT code — report with an unlisted code.
Use web-based prior authorization/reporting tool
Use the online authorization tool and related web-based prior authorization processes referenced in the policy for submission and reporting of unlisted procedures; follow tool prompts for the medical criteria required for coverage determinations.
- Submit prior authorization requests via the web-based authorization tool referenced in the related policy.
- For unlisted whole‑body hyperthermia procedures, report using the web-based prior authorization process as instructed.
Submit prior authorization via web tool and include supporting documentation
Prior authorization requests must be submitted through the web-based tool; Medicare Advantage requires prior authorization and Commercial products are recommended to use the tool. Documentation supporting that the online authorization tool medical criteria are met should be provided as part of the request.
- Provide documentation demonstrating that the medical criteria in the online authorization tool are met for Medicare Advantage determinations.
- Use the web-based tool for prior authorization and for reporting unlisted procedures per the related policy.
Denial triggers — unmet authorization criteria and whole‑body hyperthermia excluded
Claims may be denied if the medical criteria in the online authorization tool are not met; whole‑body hyperthermia therapy is not covered for Medicare Advantage and is not medically necessary for Commercial products.
- Local hyperthermia: denials can occur when online authorization tool criteria are not satisfied.
- Whole‑body hyperthermia: not covered for Medicare Advantage and not medically necessary for Commercial products due to insufficient evidence.
Clinical Background
Hyperthermia exposes body tissue to elevated temperatures (reported up to 113°F) to damage and kill cancer cells and increase tumor susceptibility to other therapies. Local hyperthermia raises the temperature of superficial or subcutaneous tumors using external or interstitial modalities while sparing surrounding normal tissue and may be used in combination with radiation therapy for primary or metastatic cutaneous or subcutaneous superficial tumors. Whole-body hyperthermia involves placing the patient under general anesthesia or deep sedation, increasing core temperature (example cited to 108°F) for an extended period (maintained for about 4 hours with additional cooling and observation), and requires prolonged monitoring; this modality is considered not medically necessary due to inadequate evidence.
Definitions
Policy Revision History
Policy effective date published as 08/01/2025.
Policy last reviewed on 04/02/2025.
Provider Update published June 2025 noting policy publication in Provider Update communications.
Provider Update published March 2024 (listed in policy publications history).
Provider Update published April 2023 (listed in policy publications history).
Provider Update published June 2022 (listed in policy publications history).
Provider Update published May 2021 (listed in policy publications history).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.